Multicenter parallel phase II trials of the polo-like kinase 1 inhibitor BI-2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. : The first protocol of the European Organisation for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

Schöffski, Patrick;Blay, J. Y.;De Greve, J.;Brain, E.;Lacombe, D.;et.al.
(2009) 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology — Location: Berlin(Germany) (20.September.2009)

Files

58661.pdf
  • Restricted Access
  • Adobe PDF
  • 1.2 MB

Details

Authors
  • Schöffski, PatrickKUL
    Author
  • Blay, J. Y.
    Author
  • De Greve, J.
    Author
  • Brain, E.
    Author
  • Author
  • Lacombe, D.
    Author
Show more
Affiliations

Citations

Schöffski, P., Blay, J. Y., De Greve, J., Brain, E., Machiels, J.-P., Soria, S. C., Sleijfer, S., Munzert, G., Rapion, J., & Lacombe, D. (2009). Multicenter parallel phase II trials of the polo-like kinase 1 inhibitor BI-2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. : The first protocol of the European Organisation for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). EJC - Supplements, 7(2), 138-139. https://hdl.handle.net/2078.5/146916 (Original work published 2009)